Biocon Biologics names Kedar Upadhye as new CFO
Biocon Biologics on Thursday announced it has appointed Kedar Upadhye as its new CFO.
Upadhye will be replace current CFO MB Chinappa who will take up strategic finance role at Biocon Group and will work with Peter Bains, the recently appointed Group CEO of Biocon.
The leadership changes will be effective October 31, 2023, Biocon Biologics said in a statement.
«He (Kedar) joins us at an inflection point in our journey to become a leading global biosimilars company as we look to consolidate and unlock value in the acquired business,» said Shreehas Tambe, CEO and MD of Biocon Biologics.
«I am confident that he will build further on the strong foundation and with his expertise and experience work closely with all stakeholders to drive growth and deliver on our business goals,” Tambe added.
Upadhye brings with him over 23 years of experience in senior global leadership roles at leading pharma, energy and FMCG companies such as Cipla, Dr.
Reddy’s, PepsiCo, and Thermax.
In his previous assignment, Upadhye was CFO of ReNew Energy Global Plc.
